Withdrawal of statins increases event rates in patients with acute coronary syndromes

Circulation

Volumn 105, Issue 12, 2002, Pages 1446-1452

  Heeschen, Christopher ^a   Hamm, Christian W ^a   Laufs, Ulrich ^a   Snapinn, Steven ^a   Böhm, Michael ^a   White, Harvey D ^a  

^a KERCKHOFF HEART CENTER   (Germany)

Author keywords

Angina; Coronary disease; Ischemia; Prognosis; Statins

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRATE; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; TROPONIN T;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ST SEGMENT; SYMPTOM; THORAX PAIN;

ACUTE DISEASE; CHOLESTEROL; CLINICAL TRIALS; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOVASTATIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SIMVASTATIN; SUBSTANCE WITHDRAWAL SYNDROME; SURVIVAL RATE; TREATMENT OUTCOME; TROPONIN; UNITED STATES;

EID: 0037177167     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000012530.68333.C8     Document Type: Article

References (29)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study
6. Current perspectives on statins
7. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
8. Statins do more than just lower cholesterol
9. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
10. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
11. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis: CAPTURE Investigators: Chimeric c7E3 Anti-Platelet Therapy in Unstable angina REfractory to standard treatment trial
12. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
13. Inflammation, atherosclerosis, and ischemic events: Exploring the hidden side of the moon
14. Atherosclerosis an inflammatory disease
15. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
16. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
17. Inflammatory alterations in the myocardial microcirculation
18. NO: The primary EDRF
19. Inducible nitric oxide synthase and vascular injury
20. Nitric oxide and the proliferation of vascular smooth muscle cells
21. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
22. Increased thrombotic vascular events after change of statin
23. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
24. Improved troponin T ELISA specific for cardiac troponin T isoform: Assay development and analytical and clinical validation
25. Regression models in clinical studies: Determining relationships between predictors and response
26. Statins as a newly recognized type of immunomodulator
27. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway
28. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
29. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial